Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent Paraganglioma/Pheochromocytoma
NCT00843037Phase 2Completed
- Sponsor
- University Health Network
- Start
- Feb 2009
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Paraganglioma (PGL) and pheochromocytoma, sponsored by University Health Network. Primary endpoints: Clinical Benefit Rate at 12 weeks, Toxicity Profile and 1 more. Started Feb 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
Paraganglioma (PGL)pheochromocytoma
Beyond the preview
Go deeper on NCT00843037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843037.